tetano
Editor, Senior Moderator
Virology. 2019 Jul 8;535:179-188. doi: 10.1016/j.virol.2019.07.008. [Epub ahead of print]
[h=1]Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.[/h] Kim KH[SUP]1[/SUP], Lee YT[SUP]1[/SUP], Park S[SUP]1[/SUP], Jung YJ[SUP]1[/SUP], Lee Y[SUP]1[/SUP], Ko EJ[SUP]1[/SUP], Kim YJ[SUP]1[/SUP], Li X[SUP]2[/SUP], Kang SM[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Neuraminidase is the second major surface antigen on influenza virus. We investigated the immunogenicity and cross protective efficacy of virus-like particle containing neuraminidase derived from 2009 pandemic H1N1 influenza virus (N1 VLP) in comparison with inactivated split influenza vaccine. Immunization of mice with N1 VLP induced antibody responses specific for virus and cross-reactive neuraminidase inhibition activity whereas an inactivated split vaccine induced strain-specific hemagglutination inhibition activity. N1 VLP-immunized mice developed cross protective immunity against antigenically different influenza viruses, as determined by body weight changes, lung viral titers, infiltrating innate immune cells, and cytokines, and antibody secreting cells, and germinal center B cells. Also, N1 VLP-immune sera provided cross-protection in na?ve mice. Immunity by N1 VLP vaccination was not compromised in Fc receptor γ-chain deficient mice. These results suggest that neuraminidase-presenting VLP can be developed as an effective cross-protective vaccine candidate along with current influenza vaccination.
Crown Copyright ? 2019. Published by Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] Cross protection; Influenza virus; Neuraminidase vaccine; Virus-like particle
PMID: 31310875 DOI: 10.1016/j.virol.2019.07.008
[h=1]Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.[/h] Kim KH[SUP]1[/SUP], Lee YT[SUP]1[/SUP], Park S[SUP]1[/SUP], Jung YJ[SUP]1[/SUP], Lee Y[SUP]1[/SUP], Ko EJ[SUP]1[/SUP], Kim YJ[SUP]1[/SUP], Li X[SUP]2[/SUP], Kang SM[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Neuraminidase is the second major surface antigen on influenza virus. We investigated the immunogenicity and cross protective efficacy of virus-like particle containing neuraminidase derived from 2009 pandemic H1N1 influenza virus (N1 VLP) in comparison with inactivated split influenza vaccine. Immunization of mice with N1 VLP induced antibody responses specific for virus and cross-reactive neuraminidase inhibition activity whereas an inactivated split vaccine induced strain-specific hemagglutination inhibition activity. N1 VLP-immunized mice developed cross protective immunity against antigenically different influenza viruses, as determined by body weight changes, lung viral titers, infiltrating innate immune cells, and cytokines, and antibody secreting cells, and germinal center B cells. Also, N1 VLP-immune sera provided cross-protection in na?ve mice. Immunity by N1 VLP vaccination was not compromised in Fc receptor γ-chain deficient mice. These results suggest that neuraminidase-presenting VLP can be developed as an effective cross-protective vaccine candidate along with current influenza vaccination.
Crown Copyright ? 2019. Published by Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] Cross protection; Influenza virus; Neuraminidase vaccine; Virus-like particle
PMID: 31310875 DOI: 10.1016/j.virol.2019.07.008